Transmission of human parvovirus B19 by plasma derived factor VIII concentrates.
Although clotting factor concentrates prepared from large pools of plasma are considered to be safe for enveloped viruses (HIV, HBV and HCV), these products are likely to remain at risk for non lipid enveloped viruses. The prevalence of positive IgG serology for human parvovirus B19 (HPV-B19) was determined in 53 children suffering from haemophilia A, who had been treated from birth with only one brand of a highly purified factor VIII concentrate prepared by ion exchange chromatography with a solvent-detergent step (HPSD-VIII). HPV-B19 seropositivity ranged from 20 to 43% in 198 age matched controls. In contrast, the incidence of positive HPV-B19 IgG serology varied from 75 to 100% in haemophiliacs and all 10 severe haemophilia A patients under 3 years of age were seropositive. The presence of HPV-B19 in this clotting factor concentrate demonstrates that at least a proportion of such products continue to transmit non lipid enveloped viruses.
Laurian
Y
Y
Centre de Traitement pour Hémophiles, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
Dussaix
E
E
Parquet
A
A
Chalvon-Demersay
A
A
d'Oiron
R
R
Tchernia
G
G
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002852:Chromatography, Ion Exchange; D016731:Erythema Infectiosum / Q000150:complications / Q000453:epidemiology / Q000276:immunology / Q000635:transmission*; D005169:Factor VIII / Q000009:adverse effects* / Q000302:isolation & purification; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D015994:Incidence; D007223:Infant; D016732:Parvovirus B19, Human / Q000502:physiology*; D015995:Prevalence
D007074:Immunoglobulin G; D005169:Factor VIII